{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-034711","form_type":"8-K","ticker":"BIAF","cik":"0001712762","company_name":"bioAffinity Technologies, Inc.","filed_at":"2026-07-27T12:30:31+00:00","discovered_at":"2026-07-27T12:35:00.268854+00:00","generated_at":"2026-07-27T12:35:26.108350+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"bioAffinity Technologies publishes clinical framework for CyPath Lung in nodule evaluation","bullets":["White paper by CMO Gordon Downie proposes specialty-specific pathways for pulmonology, primary care, oncology using CyPath Lung.","CyPath Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy, 99% NPV in high-risk patients with small nodules.","Company reports 7.78M shares outstanding, market cap ~$5.1M as of July 24, 2026.","CyPath Lung analyzes sputum for lung microenvironment, not blood-based, providing real-time information.","Complete white paper available at https://bit.ly/cypath-lung-whitepaper3."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-034711","json":"https://secwatch.observer/filing/0001493152-26-034711.json","markdown":"https://secwatch.observer/filing/0001493152-26-034711.md","text":"https://secwatch.observer/filing/0001493152-26-034711.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1712762/000149315226034711/0001493152-26-034711-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1712762/000149315226034711/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-27T12:35:26.108350+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}